After multivariable adjustment , there were no differences in clinical outcomes at 1 year between the groups , including major adverse cardiac events ( MACE ) ( HR 0.94 ( 95 % CI 0.76 to 1.16 ) , p = 0.55 ) , mortality ( HR 1.03 ( 0.65 to 1.62 ) , p = 0.91 ) , myocardial infarction ( MI ) ( HR 1.07 ( 0.83 to 1.38 ) , p = 0.60 ) and unplanned target vessel revascularisation ( TVR ) ( HR 0.95 ( 0.71 to 1.28 ) , p = 0.75 ) .